儿童、青少年和成人肾细胞癌患者接受阿西替尼治疗后的疗效：综述。

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2024-09-24 DOI:10.1016/j.critrevonc.2024.104523

Julia Sprokkerieft , Justine N. van der Beek , Filippo Spreafico , Barbara Selle , Tanzina Chowdhury , Norbert Graf , Arnauld C. Verschuur , Rana Dandis , Axel Bex , James I. Geller , Godelieve A.M. Tytgat , Marry M. van den Heuvel-Eibrink

{"title":"儿童、青少年和成人肾细胞癌患者接受阿西替尼治疗后的疗效：综述。","authors":"Julia Sprokkerieft , Justine N. van der Beek , Filippo Spreafico , Barbara Selle , Tanzina Chowdhury , Norbert Graf , Arnauld C. Verschuur , Rana Dandis , Axel Bex , James I. Geller , Godelieve A.M. Tytgat , Marry M. van den Heuvel-Eibrink","doi":"10.1016/j.critrevonc.2024.104523","DOIUrl":null,"url":null,"abstract":"<div><div>Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for treatment of RCC in adults, but its effects in children and young adults with RCC remains unclear. Due to the histological and biological differences between children and adults, it is difficult to extrapolate knowledge on treatments from the adult to the pediatric and young adult setting. This paper summarizes the clinical characteristics and outcomes of patients with RCC who were treated with axitinib, with the aim to gain insight in the clinical efficacy of this compound in this young patient group.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104523"},"PeriodicalIF":5.5000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review\",\"authors\":\"Julia Sprokkerieft , Justine N. van der Beek , Filippo Spreafico , Barbara Selle , Tanzina Chowdhury , Norbert Graf , Arnauld C. Verschuur , Rana Dandis , Axel Bex , James I. Geller , Godelieve A.M. Tytgat , Marry M. van den Heuvel-Eibrink\",\"doi\":\"10.1016/j.critrevonc.2024.104523\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for treatment of RCC in adults, but its effects in children and young adults with RCC remains unclear. Due to the histological and biological differences between children and adults, it is difficult to extrapolate knowledge on treatments from the adult to the pediatric and young adult setting. This paper summarizes the clinical characteristics and outcomes of patients with RCC who were treated with axitinib, with the aim to gain insight in the clinical efficacy of this compound in this young patient group.</div></div>\",\"PeriodicalId\":11358,\"journal\":{\"name\":\"Critical reviews in oncology/hematology\",\"volume\":\"204 \",\"pages\":\"Article 104523\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2024-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical reviews in oncology/hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S104084282400266X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S104084282400266X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

肾细胞癌（RCC）是儿童和年轻人中非常罕见的一种肾癌。一旦发生转移或复发，目前尚无标准的治疗方法，而且疗效仍然不佳。酪氨酸激酶抑制剂阿西替尼已被批准用于治疗成人 RCC，但其对儿童和青少年 RCC 患者的疗效仍不明确。由于儿童和成人在组织学和生物学方面存在差异，因此很难将成人的治疗知识推广到儿童和青少年患者中。本文总结了接受阿西替尼治疗的RCC患者的临床特征和疗效，旨在深入了解这种化合物在这一年轻患者群体中的临床疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review

Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for treatment of RCC in adults, but its effects in children and young adults with RCC remains unclear. Due to the histological and biological differences between children and adults, it is difficult to extrapolate knowledge on treatments from the adult to the pediatric and young adult setting. This paper summarizes the clinical characteristics and outcomes of patients with RCC who were treated with axitinib, with the aim to gain insight in the clinical efficacy of this compound in this young patient group.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.